A 48-year-old man with a medical history of hypertension and no family history of prostate cancer presented with abdominal distension, lower abdominal pain, and lower urinary symptoms. Physical examination revealed a palpable mass in the lower abdomen, and a digital rectal examination detected a firm mass on the anterior side of the rectum. Laboratory tests showed an elevated PSA level (7.9 ng/mL). Imaging studies indicated a solid mass connected to the prostate’s posterior and rectum’s anterior walls, along with bladder compression. Transperitoneal biopsy and histological analysis led to a diagnosis of a stromal tumor with uncertain potential malignancy. Considering the absence of apparent malignancy signs and the smooth outer wall of the tumor, the patient underwent, for the first time in the literature, a robot-assisted radical extraperitoneal prostatectomy for complete macroscopic resection. The surgery involved excision of the bulky pelvic mass, preservation of the urethra, and anatomical reconstruction. The postoperative course was uneventful, and we discharged the patient with no complications. The pathological examination documented the diagnosis of multilocular prostatic cystadenoma. Post-surgery follow-up examinations, including PSA levels and imaging scans, showed no signs of tumor recurrence. At the 3-, 6-, and 9-month follow-ups, the patient was asymptomatic and had fully recovered, with no urinary or sexual dysfunction reported.

Journal Section:
Case Report
Keywords:
Giant multilocular prostatic cystadenoma, Benign prostatic tumor, Pelvic mass, Extraperitoneal robotic surgery, Obstructive symptoms
1.
Scarcia M, Maselli FP, Cardo G, Pagliarulo G, Ludovico GM. Robot-assisted excision of seminal vesicle cyst associated with ipsilateral renal agenesis. Arch Ital Urol Androl. 2016;87(4):325–6.
https://doi.org/10.4081/aiua.2015.4.325
2.
Murer LM, Talmon GA. Stromal tumor of uncertain malignant potential of the prostate. Arch Pathol Lab Med. 2014;138(11):1542–5.
https://doi.org/10.5858/arpa.2013-0212-RS
3.
Scarcia M, Zazzara M, Divenuto L, Cardo G, Portoghese F, Romano, M, et al. Extraperitoneal robot-assisted radical prostatectomy: a high-volume surgical center experience. Minerva Urol E Nefrol Ital J Urol Nephrol. 2018;70(5):479–85.
https://doi.org/10.23736/S0393-2249.18.03114-4
4.
Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, et al. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. Prostate Cancer Prostatic Dis. 2022.
https://doi.org/10.1038/s41391-022-00609-3
5.
Nakamura Y, Shida D, Shibayama T, Yoshida A, Matsui Y, Shinoda Y, et al. Giant multilocular prostatic cystadenoma. World J Surg Oncol. 2019;17(1):42.
https://doi.org/10.1186/s12957-019-1579-7
6.
Wang W, Xiao Y, Fang S, Qiao Y, Rong S, Wang F, et al. Case report: giant unilocular prostate cystadenoma: a rarer condition with a single cystic mass. Front Oncol. 2022;12:911442.
https://doi.org/10.3389/fonc.2022.911442
7.
Chen J, Zhang W, Chen H, Wang Y, Li Z, Wu H, et al. Imaging and clinical features of giant multilocular prostatic cystadenoma: a case report. Medicine. 2020;99(41):e22666.
https://doi.org/10.1097/MD.0000000000022666
8.
Portugal Teixeira I, Pereira PR, Silva A, Castro M. Giant multilocular prostatic cystadenoma, a diagnosis to consider in large pelvic male masses. Radiol Case Rep. 2019;14(12):1473–7.
https://doi.org/10.1016/j.radcr.2019.09.017
9.
Hauck EW, Battmann A, Schmelz HU, Diemer T, Miller J, Weidner W, et al. Giant multilocular cystadenoma of the prostate: a rare differential diagnosis of benign prostatic hyperplasia. Urol Int. 2004;73(4):365–9.
https://doi.org/10.1159/000081602
10.
Uguen A, Doucet L, Badic B, Perrouin-Verbe MA, Valeri A, Bail JP, et al. Cystic epithelial tumors of the prostate: one case supporting a continuous spectrum from cystadenoma to cystadenocarcinoma with ductal features. Am J Surg Pathol. 2016;40(12):1719–21.
https://doi.org/10.1097/PAS.0000000000000726
11.
Datta MW, Hosenpud J, Osipov V, Young RH. Giant multilocular cystadenoma of the prostate responsive to GnRH antagonists. Urology. 2003;61(1):225.
https://doi.org/10.1016/s0090-4295(02)02109-x
12.
Choi TS, Lee DG, Yoo KH, Min G-E. Rapid recurrence of giant multilocular prostatic cystadenoma after laparoscopic excision for primary case: a case report. Medicina. 2021;57(9):870.
https://doi.org/10.3390/medicina57090870
13.
Moretto S, Gandi C, Bientinesi R, Totaro A, Marino F, Gavi F, et al. Robotic versus open pyeloplasty: perioperative and functional outcomes. J Clin Med. 2023;12(7):2538.
https://doi.org/10.3390/jcm12072538
14.
Zeng XW, Zhu SX, Xu YP, Zheng LF, Wang ZP, Chen JC, et al. Giant dumbbell-shaped prostatic cystadenoma presenting as pelvic and scrotal mass. J Pak Med Assoc. 2021;71(2(B)):759–62.
https://doi.org/10.47391/JPMA.1169
15.
Sushentsev N, Rimmer Y, Barrett T. Complete resolution of a giant multilocular prostatic cystadenoma following androgen deprivation therapy: an illustrative case report. Oxf Med Case Rep. 2021;2021(7):omab053. omab053.
https://doi.org/10.1093/omcr/omab053
16.
Saadi MH, Saadi A, Charkoun M, Saadi C, Ghorbel Z, Bouafif M, et al. Prostatic cystadenoma presenting as a large multilocular pelvic male mass. J Surg Case Rep. 2020;2020(8):rjaa244.
https://doi.org/10.1093/jscr/rjaa244
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.